Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GE KUBio: New Plans in China

GE KUBio: General Electric Company (NYSE:GE) and JHL Biotech have reached an agreement over the construction of a KUBio modular facility. Through its business unit, GE Healthcare Life Sciences, GE, will provide the Chinese biopharmaceuticals company a cGMP-compliant designed facility equipped for bio-manufacturing. The facility will be located at the Biolake Science Park in Wuhan, and is expected to be fully running by early 2015. This deadline is compliant with KUBio’s promise of setting up a ready-to-run bioprocessing facility within 14-18 months.

General Electric Company (NYSE:GE)

The facility is presented by GE as an off-the-shelf solution to manufacturing needs for monoclonal antibodies. The preassembled units provide a fully-functional bioprocessing facility designed to deliver a rapid response to local healthcare requirements. The facility fits right into JHL’s goals for making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation. The agreement is also a reflection of a worldwide increasing demand for biopharmaceuticals, especially antibodies for the treatment of cancer and a new generation of innovative vaccines.

The facility is expected to have a floor space of approximately 2,400m2, but GE did not specify the number of 2,000L single use-reactors. GE has said it will take full responsibility for assembly at location, and to take a team from its Shanghai Fast Track team to test the facility before turning it over to JHL.

“The decision of JHL Biotech’s highly experienced team to select KUBio as the basis of its commercial cGMP biopharmaceutical manufacturing capabilities in China is a fantastic endorsement of our complete, turnkey approach. We look forward to working with them to bring the facility online to serve the fast-moving biopharmaceutical industry. A diverse range of customers, including governments and pharmaceutical companies, are continuing to recognise the breadth, depth, simplicity and flexibility of what we offer with KUBio,” said Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences.

“In realising our vision of making world-class biopharmaceuticals affordable and accessible to all patients, KUBio was the natural choice. Utilizing manufacturing innovations was always a key part of our strategy and GE Healthcare’s KUBio delivers the technologies we want, with the technical support and training we need,” commented Racho Jordanov, Co-founder, President and CEO of JHL Biotech. Check back here for more updates on GE KUBio.

Disclosure: Jodor Jalit holds no position in any of the mentioned stocks.

Recommended Reading:

Arab Spring Effects on General Electric

General Electric Company (GE), Apple Inc. (AAPL), Koninklijke Philips NV (ADR) (PHG): Can This Tech Giant Cross Over From Smartphones Into Health Care?

How Dividends Change the Game for General Electric Company (GE) Stock

Loading...